Open AccessMelanocortin receptors in GtoPdb v.2021.3
Author(s) -
Vanni Caruso,
Biaoxin Chai,
Adrian Clark,
Roger D. Cone,
Alex N. Eberlé,
Sadaf Farooqi,
Tung M. Fong,
Ira Gantz,
Carrie HaskellLuevano,
Victor J. Hruby,
Kathleen G. Mountjoy,
Colin W. Pouton,
Helgi B. Schiöth,
Jeffrey B. Tatro,
Jarl E. S. Wikberg
Publication year - 2021
Publication title -
iuphar/bps guide to pharmacology cite
Language(s) - English
Resource type - Journals
ISSN - 2633-1020
DOI - 10.2218/gtopdb/f38/2021.3
Subject(s) - melanocortin , receptor , melanocortin 3 receptor , acth receptor , endocrinology , endogeny , medicine , melanocortin receptor , biology , pharmacology , adrenocorticotropic hormone , hormone
Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test, whilst NDP-MSH was approved by EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.